U.S. market Closed. Opens in 1 day 11 hours 24 minutes

ATRA | Atara Biotherapeutics, Inc. Stock Fundamentals

(Stock Exchange: NASDAQ)
Analyzing fundamentals for ATRA we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is on medium level and Health is frighteningly weak.

Valuation (10%)

Company Industry
P/E Ratio (TTM) -0.08 -15.27
PEG Ratio (TTM) 0.00 -4.35
P/S Ratio (TTM) 0.57 45.97
P/B Ratio (TTM) -0.82 28.96
P/FCF Ratio (TTM) -0.60 -2.59
Price to 5YR AVG Earnings Ratio -0.01 -5.56
Price to 5YR AVG FCF Ratio -0.25 -12.33

Profitability (25%)

Company Industry
ROA (TTM) -674.80% -19.06%
ROE (TTM) 965.52% 15.70%
Net Profit Margin (TTM) -958.77% -813.88%
ROIC 5YR AVG -202.16% 3.12%

Growth (60%)

4QTR AVG 3YR AVG 5YR AVG
EPS 31.24% 10.54% 10.70%
Revenue 171.82% N/A 25.21%
Net Income 34.96% -14.15% 15.67%
Cash Flow 42.42% -9.93% -4.76%

Health (7%)

Company Industry
Current Ratio (TTM) 0.59 5.56
Quick Ratio (TTM) 0.50 5.34
D/E Ratio (TTM) N/A 0.95
Interest Coverage (TTM) -25.09 -6.44
Piotroski F-Score 2 5
Altman Z-Score N/A 12.45
LTL to 5YR AVG FCF -0.20 0.11
Shares Outstanding Growth 5YR AVG 20.13% 37.46%
An error has occurred. This application may no longer respond until reloaded. Reload 🗙